Head to Head Comparison: Echo Therapeutics (OTCMKTS:ECTE) versus IQVIA (NYSE:IQV)

IQVIA (NYSE:IQV) and Echo Therapeutics (OTCMKTS:ECTE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and earnings.

Analyst Recommendations

This is a summary of recent ratings for IQVIA and Echo Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IQVIA	0	2	13	2	3.00
Echo Therapeutics	0	0	0	0	0.00

IQVIA presently has a consensus target price of $229.13, suggesting a potential upside of 35.53%. Given IQVIA’s stronger consensus rating and higher probable upside, equities analysts clearly believe IQVIA is more favorable than Echo Therapeutics.

Profitability

This table compares IQVIA and Echo Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IQVIA	8.34%	30.50%	6.57%
Echo Therapeutics	N/A	N/A	N/A

Insider & Institutional Ownership

89.6% of IQVIA shares are owned by institutional investors. 1.7% of IQVIA shares are owned by company insiders. Comparatively, 7.0% of Echo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares IQVIA and Echo Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IQVIA	$16.31 billion	1.76	$1.36 billion	$7.86	21.51
Echo Therapeutics	N/A	N/A	N/A	N/A	N/A

IQVIA has higher revenue and earnings than Echo Therapeutics.

Summary

IQVIA beats Echo Therapeutics on 9 of the 10 factors compared between the two stocks.

About IQVIA

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients’ outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.

About Echo Therapeutics

Echo Therapeutics, Inc. is a medical device company, which engages in the development of non-invasive, and wireless continuous glucose monitoring system for use in the diabetes outpatient market. It offers needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose and delivery of topical pharmaceuticals. The company was founded in 1989 and is headquartered in Iselin, NJ.